Mark Schoenberg Sells 10,000 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00. Following the transaction, the insider directly owned 129,763 shares of the company’s stock, valued at approximately $4,543,002.63. This trade represents a 7.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Stock Performance

URGN stock opened at $34.38 on Friday. The firm has a market cap of $1.67 billion, a PE ratio of -12.50 and a beta of 1.59. The firm’s fifty day moving average is $28.24 and its 200 day moving average is $23.28. Urogen Pharma has a one year low of $12.73 and a one year high of $36.08.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. Research analysts predict that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on URGN. D. Boral Capital reissued a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a report on Tuesday, March 31st. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 price target for the company. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.50.

Hedge Funds Weigh In On Urogen Pharma

A number of hedge funds have recently made changes to their positions in URGN. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in Urogen Pharma in the 4th quarter valued at $206,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.